Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery

    November 2025 in “ Journal of Medicinal Chemistry
    Laura Gioiello, Rita Maria Concetta Di Martino, Tracey Pirali
    TLDR Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
    Proteolysis-targeting chimeras (PROTACs) are being explored for topical use to achieve localized protein degradation with reduced systemic toxicity. This article discusses advances in topical PROTACs, highlighting androgen receptor degraders AH-001 and GT20029, which are in clinical trials for androgenetic alopecia, with GT20029 also being tested for acne. The scope of PROTACs is expanding to target proteins like JAK kinases and BET family members, with potential applications in dermatology, pulmonary and ocular diseases, and cosmetics. Innovative delivery methods, such as liposomes and microneedle systems, are enhancing local delivery. However, challenges remain in optimizing stability, tissue penetration, and target engagement. The article suggests strategic directions to advance the clinical application of topical PROTACs.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 44 results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  135 upvotes 1 year ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Is GT20029 supposed to regrow hair as well?

      in Treatment  9 upvotes 2 years ago
      The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

      community Silicon Valley backed company aims to cure hair loss

      in Technology  54 upvotes 3 years ago
      A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

      community bro where tf is GT20029, Q1 2024 is over already

      in Research/Science  41 upvotes 1 year ago
      The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

      community Kintor does not have abandoned KX-826 - ANNUAL RESULTS 2023

      in Product  7 upvotes 1 year ago
      The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

    Similar Research

    5 / 35 results